<DOC>
	<DOCNO>NCT01262391</DOCNO>
	<brief_summary>This single-dose study investigate well solifenacin suspension take , long stay body well tolerated child adolescent age 5-17 year symptoms overactive bladder .</brief_summary>
	<brief_title>Single-dose Study Assess Pharmacokinetics Solifenacin Succinate Suspension Children Adolescents</brief_title>
	<detailed_description>This multicenter , open-label , sequential , single ascend dose study . The study consist three treatment group child three treatment group adolescent , target equivalent exposure 2.5 , 5 10 mg dos o.d . adult steady state . The study conduct pediatric OAB patient establish single-dose PK acute safety profile solifenacin aqueous suspension . Each six group consist least six patient . The study start low dose group adolescent patient ( 12 17 year ) . When group complete study , safety concentration data review Safety Review Committee . If safety concern evident accord pre-specified criterion , enrollment child ( 5 11 year ) low dose group adolescent intermediate dose group start simultaneously . When group complete study , safety data drug concentration data also review . If safety concern occur , enrollment child intermediate dose group adolescent high dose group start simultaneously . Finally , group complete study safety concern occur associate data review , enrollment child high dose group start . Interim review plasma exposure low dos use adjust next high dos administer , necessary .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Symptoms urgency , diagnose OAB accord International Children 's Continence Society ( ICCS ) criterion Daytime urgency incontinence least once/day Daytime void frequency le 5 Uroflow indicative pathology OAB Maximum void volume &gt; age expect capacity ( [ age +1 ] x 30 ) ml Post void residual ( PVR ) &gt; 10 % functional bladder capacity Monosymptomatic enuresis Congenital anomalies genitourinary tract nervous system Current constipation ( treated patient enter study ) Current urinary tract infection ( patient eligible enrolment 14 day negative dipstick test , provide second dipstick test , perform 14 day , also negative ) Serum creatinine equal 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) equal 2 time ULN , bilirubin equal 1.5 time ULN</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Overactive bladder</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Single-dose</keyword>
	<keyword>Solifenacin suspension</keyword>
</DOC>